(Total Views: 1126)
Posted On: 03/18/2021 4:44:51 PM
Post# of 148902
These intentionally malicious, and insidious lies are meant to cause fear, confusion, panic, in order to erode your trust of yourself, and a company that has a therapeutic that works in saving lives.
"Bronstein Gewirts & Grossman" shareholder alerts are utter and complete nonsense, a total sack of lies, along with "Scott + Scott, Kessler Topax Meltzer & Check, Pomerantz Law", the likes blasting across our updates daily in recent reposts of threats of litigation which are simply scare tactics. Words like "insolvency","bankruptcy","investigation", just because Trump said drink Chlorine, it'll kill the virus, doesn't mean you should believe it. Just like that, don't drink these "law offices" Kool Aid either.
They want you to join their class action lawsuit?! Pathetic.They were the ones who pretended to sue CYDY last year in support of the run up to the massive short attack on June 30th 2020. They're the ones who put up a STAT article and then pulled it a few hours after. They're the same ones who tried to campaign in a coordinated attack across multiple sites to destroy CYDY last year, and failed. They're going to fail again this time, because we have ever BETTER data than ever! Oho guess what we have on our side? Science. Science ladies and gentlemen! Science, WILL Prevail.
Fact: NP and SK sold shares in order to make payments to Samsung, they forfeited effectively their own future pay to keep the drug manufacturing running smoothly.
Any sleazeball trying to spin that in ALL of the articles across the internet, all of these years, are all spinning the same deceit and lies, trying to paint a hardworking group of good people as anything but. It's tiresome, and annoying, if you let it bother you.
I watched it happen in real time. Disgusting these "lawyers" and shorts, and now they're trying to get your information to further scare you and basically burn the company because hey guess what, they have a product that works.
Don't fall for it new investors. We longs have seen this before, and we're going to continue to see this.
Didn't one of these firms addresses actually turn out to be some empty parking lot according to google maps? Another turned out to be some other storefront altogether.
Trust the science. Don't even bother reading this sneers and jeers from the sidelines, it's nothing more than playground bullying across the internet.
Next!
Let's refocus on the science here people. The data is the data, and the data shows, Leronlimab WORKS. If you need some more proof, reread Jay's open letter, which he has be advocating for over a year now (pro140 that is):
" March 10, 2021
Dear Dr. Woodcock,
The FDA has protected the American public during Covid by issuing various EUAs, but no treatment has been advanced that specifically helps our most vulnerable citizens-those who are critically ill. And unfortunately, with variant strains now circulating, a potential 4th wave is possible.
CytoDyn’s CD12 trial is the first randomized, double-blind, placebo-controlled study to suggest a striking survival benefit for critically ill Covid patients (24% reduced mortality; p value nss). The study demonstrates statistical significance on a variety of crucial secondary endpoints including shortened hospital stay (6 days; P=0.005), improved survival in patients who received SOC therapy (N=309; P=0.031), and improved survival in patients under 65 years of age, including both all patients under 65 (N=221; P=0.02) and well as those who were critically ill (N=44; P=0.006). The study also demonstrated no safety concerns, consistent with the benign safety profile seen in about 1,000 other HIV+, cancer, and Covid patients who have received leronlimab. The unfortunate imbalance in randomization of patients > 65 years of age (and especially > 75 years) in the CD12 study should not, however, prevent patient access to a potentially life saving medication now while a study of additional critically ill patients is underway. Taken together, the CD12 efficacy signals in critically ill patients combined with the consistently benign safety profile, provide a compelling risk:benefit ratio and ample justification for FDA to issue an EUA for leronlimab for this population now.
I am consulting in the care of a 57 year old man with critical Covid who was on ECMO for 61 days at St. Thomas hospital in London. He received emergency leronlimab on day 79 of his hospitaliztion and starting weaning off ECMO 4 days later. I have attached the case report below, which has been peer reviewed and accepted for publication. Please give it your consideration. Though anecdotal, this case underscores the dramatic recovery that is possible with leronlimab even in the most critically ill patients with Covid.
I have been an independent investigator on about 50 POC studies of novel antiviral agents over the last 31 years (including HIV, CMV, HCV, HBV, HSV, HPV, and Influenza). Also, I have no equity stake in this.
I know leronlimab to be safe and I believe it can help save critically ill patients with Covid-19. Please give these patients and their medical teams a fighting chance.
Respectfully,
Jacob Lalezari, MD Director, Quest Research SF, CA
"
"Bronstein Gewirts & Grossman" shareholder alerts are utter and complete nonsense, a total sack of lies, along with "Scott + Scott, Kessler Topax Meltzer & Check, Pomerantz Law", the likes blasting across our updates daily in recent reposts of threats of litigation which are simply scare tactics. Words like "insolvency","bankruptcy","investigation", just because Trump said drink Chlorine, it'll kill the virus, doesn't mean you should believe it. Just like that, don't drink these "law offices" Kool Aid either.
They want you to join their class action lawsuit?! Pathetic.They were the ones who pretended to sue CYDY last year in support of the run up to the massive short attack on June 30th 2020. They're the ones who put up a STAT article and then pulled it a few hours after. They're the same ones who tried to campaign in a coordinated attack across multiple sites to destroy CYDY last year, and failed. They're going to fail again this time, because we have ever BETTER data than ever! Oho guess what we have on our side? Science. Science ladies and gentlemen! Science, WILL Prevail.
Fact: NP and SK sold shares in order to make payments to Samsung, they forfeited effectively their own future pay to keep the drug manufacturing running smoothly.
Any sleazeball trying to spin that in ALL of the articles across the internet, all of these years, are all spinning the same deceit and lies, trying to paint a hardworking group of good people as anything but. It's tiresome, and annoying, if you let it bother you.
I watched it happen in real time. Disgusting these "lawyers" and shorts, and now they're trying to get your information to further scare you and basically burn the company because hey guess what, they have a product that works.
Don't fall for it new investors. We longs have seen this before, and we're going to continue to see this.
Didn't one of these firms addresses actually turn out to be some empty parking lot according to google maps? Another turned out to be some other storefront altogether.
Trust the science. Don't even bother reading this sneers and jeers from the sidelines, it's nothing more than playground bullying across the internet.
Next!
Let's refocus on the science here people. The data is the data, and the data shows, Leronlimab WORKS. If you need some more proof, reread Jay's open letter, which he has be advocating for over a year now (pro140 that is):
" March 10, 2021
Dear Dr. Woodcock,
The FDA has protected the American public during Covid by issuing various EUAs, but no treatment has been advanced that specifically helps our most vulnerable citizens-those who are critically ill. And unfortunately, with variant strains now circulating, a potential 4th wave is possible.
CytoDyn’s CD12 trial is the first randomized, double-blind, placebo-controlled study to suggest a striking survival benefit for critically ill Covid patients (24% reduced mortality; p value nss). The study demonstrates statistical significance on a variety of crucial secondary endpoints including shortened hospital stay (6 days; P=0.005), improved survival in patients who received SOC therapy (N=309; P=0.031), and improved survival in patients under 65 years of age, including both all patients under 65 (N=221; P=0.02) and well as those who were critically ill (N=44; P=0.006). The study also demonstrated no safety concerns, consistent with the benign safety profile seen in about 1,000 other HIV+, cancer, and Covid patients who have received leronlimab. The unfortunate imbalance in randomization of patients > 65 years of age (and especially > 75 years) in the CD12 study should not, however, prevent patient access to a potentially life saving medication now while a study of additional critically ill patients is underway. Taken together, the CD12 efficacy signals in critically ill patients combined with the consistently benign safety profile, provide a compelling risk:benefit ratio and ample justification for FDA to issue an EUA for leronlimab for this population now.
I am consulting in the care of a 57 year old man with critical Covid who was on ECMO for 61 days at St. Thomas hospital in London. He received emergency leronlimab on day 79 of his hospitaliztion and starting weaning off ECMO 4 days later. I have attached the case report below, which has been peer reviewed and accepted for publication. Please give it your consideration. Though anecdotal, this case underscores the dramatic recovery that is possible with leronlimab even in the most critically ill patients with Covid.
I have been an independent investigator on about 50 POC studies of novel antiviral agents over the last 31 years (including HIV, CMV, HCV, HBV, HSV, HPV, and Influenza). Also, I have no equity stake in this.
I know leronlimab to be safe and I believe it can help save critically ill patients with Covid-19. Please give these patients and their medical teams a fighting chance.
Respectfully,
Jacob Lalezari, MD Director, Quest Research SF, CA
"
(30)
(1)Scroll down for more posts ▼
